Abstract:It has been demonstrated that anti-PD-1 immunotherapy may have potentially life-threatening side effect (i.e., autoimmune myocarditis with consequent cardiac failure). The purpose of this work was to determine the incidence and severity of radiation-induced cardiac mortality and morbidity in a murine model when cardiac irradiation is delivered concurrently with an anti-PD-1 antibody. Single fraction (20 Gy) was delivered specifically to the heart of female C57bl/6 mice with an image-guided SARRP, which allows on-board micro-CT imaging and real-time treatment planning. Mice were stratified into 4 treatment groups: (1) control IgG (n = 10); (2) anti-PD1 antibody (n = 10); (3) RT+ control IgG (n = 20); and (4) RT + anti-PD1 antibody (n = 20). Anti-CD4 and anti-CD8 antibodies were combined with RT and anti-PD1 antibody treatment to deplete subsets of T cells. Antibodies were intraperitoneally administrated 24 hours before of RT, and then every other day. Overall survival was determined. Echocardiographic assessment on all mice was performed to measure the cardiac contraction and output when clinical morbidity was encountered. The sick mice were then sacrificed for tissue collections, which were characterization by immunofluorescence for immune cells infiltration. Decreased survival was observed when anti-PD-1 was combined with RT: 35% (7/20) mortality vs. 0% mortality in other three groups (P < 0.05). The median survival following RT in the RT + Anti-PD1 group was day 8 (day 5 to 19). Ejection fraction (EF) and fractional shortening (FS) were used to measure cardiac function. Combined therapy group exhibited significantly decline in both EF and FS, especially compared with mice treated with RT + IgG control: the EFs of group 1 to 4: 62.43% ± 7.54%, 60.19% ± 5.81%, 50.85% ± 5.06%, and 38.84% ± 6.06%, P < 0.01; the FSs: 33.48% ± 5.48%, 31.66% ± 4.09%, 25.50% ± 3.13%, and 18.58% ± 3.28%, P < 0.01. These data indicates that 20 Gy induced cardiac dysfunction, which was exacerbates by anti-PD1 treatment. Myocarditis was observed in the dying mice after RT. Further immunologic data on heart tissue changed showed increased tumor infiltration by CD45, CD3, CD4, and CD8. Consistent with worse cardiac dysfunction, considerably more immune cells were observed in heart tissues of the dying mice from RT+ anti-PD1 compared with those from RT plus control IgG. To test which subset of T cells contributes to the myocarditis, neutralizing antibodies against CD4 and CD8 were combined with RT and anti-PD1 treatment. Consistently, depletion of CD8 T cells prevented mortality from RT plus anti-PD1 whereas depletion of CD4 did not, indicating that CD8+ lymphocytes mediates cardiac injury from RT + anti-PD1. The combination of PD-1 blockade increases the cardiac toxicity from irradiation through cytotoxic T cell-mediated myocarditis. Our study provides strong preclinical evidence that immune-related adverse events should be considered when PD-1 inhibitor is combined with RT.

PD-1 Modulates Radiation-Induced Cardiac Toxicity Through Cytotoxic T Lymphocytes.

Pharmacological Inhibition of PD-1 Exacerbates Radiation-Induced Cardiac Toxicity Through Cytotoxic T Cell–Mediated Myocarditis

Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade

PD-1 restrains IL-17A production from γδ T cells to modulate acute radiation-induced lung injury

Effect of PD-1 Inhibitor Combined with X-Ray Irradiation on the Inflammatory Microenvironment and Lung Tissue Injury in Mice

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications

PD-1 Inhibitor Aggravate Irradiation-Induced Myocardial Fibrosis by Regulating TGF-β1/Smads Signaling Pathway via GSDMD-Mediated Pyroptosis

Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice.

Pd-1 Inhibitors Increase the Incidence and Risk of Pneumonitis in Cancer Patients in A Doseindependent Manner: A Metaanalysis

Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

[Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine in Attenuating the Related Mortality in Mice]

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care

ATP protects anti-PD-1/radiation-induced cardiac dysfunction by inhibiting anti-PD-1 exacerbated cardiomyocyte apoptosis, and improving autophagic flux

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy

PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients

Pyrrolidine Dithiocarbamate Might Mitigate Radiation-Induced Heart Damage at an Early Stage in Rats

Adverse Cardiovascular Complications Following Prescription of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity-Score Matched Cohort Study With Competing Risk Analysis

Alleviating lung injury and pulmonary fibrosis in radiotherapy-immunotherapy combination: The role of low-dose radiation therapy.

αPD-1 immunotherapy promotes IL-17A production and promotes the formation of acute radiation-induced lung injury.

Irradiation and Anti-Pd-l1 Treatment Synergistically Promote Antitumor Immunity in Mice.